Publications by authors named "Job Schippers"

Claim this Profile
D
Disease-Drug-Drug Interaction of Imatinib in COVID-19 ARDS: A Pooled Population Pharmacokinetic Analysis.
Medhat M Said, Job R Schippers, Leila Atmowihardjo, Yingxue Li, Mick S van der Plas

CPT Pharmacometrics Syst Pharmacol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deep phenotyping of pulmonary edema and pulmonary vascular permeability in COVID-19 ARDS.
Job R Schippers, Leila N Atmowihardjo, Erik Duijvelaar, Lars G Knaap, Mihai G Netea

Am J Physiol Lung Cell Mol Physiol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The diagnostic accuracy of lung ultrasound to determine PiCCO-derived extravascular lung water in invasively ventilated patients with COVID-19 ARDS.
Leila N Atmowihardjo, Job R Schippers, Mark E Haaksma, Marry R Smit, Harm J Bogaard

Ultrasound J· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of intravenous imatinib in COVID-19 ARDS: a randomized, double-blind, placebo-controlled clinical trial.
Leila N Atmowihardjo, Job R Schippers, Erik Duijvelaar, Imke H Bartelink, Pierre M Bet

Crit Care· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of imatinib for optimal drug repurposing from cancer to COVID-19.
Nadia Baalbaki, Erik Duijvelaar, Medhat M Said, Job Schippers, Pierre M Bet

Eur J Pharm Sci· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunomodulation and endothelial barrier protection mediate the association between oral imatinib and mortality in hospitalised COVID-19 patients.
Justin de Brabander, Erik Duijvelaar, Job R Schippers, Patrick J Smeele, Hessel Peters-Sengers

Eur Respir J· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiac Safety of Imatinib for the Treatment of COVID-19: A Secondary Analysis of a Randomized, Double-Blind, Placebo-Controlled Trial.
Erik Duijvelaar, Arthur Vanhove, Job R Schippers, Patrick J Smeele, Frances S de Man

J Cardiovasc Pharmacol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term clinical outcomes of COVID-19 patients treated with imatinib.
Erik Duijvelaar, Job R Schippers, Patrick J Smeele, Michiel Alexander de Raaf, Arthur L E M Vanhove

Lancet Respir Med· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The INVENT COVID trial: a structured protocol for a randomized controlled trial investigating the efficacy and safety of intravenous imatinib mesylate (Impentri®) in subjects with acute respiratory distress syndrome induced by COVID-19.
Leila Atmowihardjo, Job R Schippers, Imke H Bartelink, Pierre M Bet, Nienke van Rein

Trials· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial.
Jurjan Aman, Erik Duijvelaar, Liza Botros, Azar Kianzad, Job R Schippers

Lancet Respir Med· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis